Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Partially Blinded, Placebo- and Comparator-Controlled, Multicenter, Phase 2a, Dose Ranging, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SPR720 as Compared With Placebo or Standard of Care for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT04553406 is registered in ClinicalTrials.gov with Spero Therapeutics as lead sponsor.

NCT NCT04553406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04553406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Partially Blinded, Placebo- and Comparator-Controlled, Multicenter, Phase 2a, Dose Ranging, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SPR720 as Compared With Placebo or Standard of Care for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
Lead sponsor
Spero Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
December 3, 2020
Completion date
January 28, 2021
Enrollment
2 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

mycobacterium avium complex, non-tuberculous mycobacterium pulmonary disease